Publications by authors named "Yaejin Woo"
Article Synopsis
- The androgen receptor (AR) is a key target for prostate cancer treatments due to its involvement in cancer progression, but current therapies have limitations, prompting the search for new strategies.
- Researchers introduced a new AR degrader called UBX-390, which outperforms existing treatments like ARV-110 and ARCC-4 in lab studies on prostate cancer cells.
- UBX-390 effectively reduces AR activity and gene expression, showing great promise for treating patients with advanced, treatment-resistant prostate cancer.
This study aimed to evaluate the antioxidant activity of various plant extracts. A total of 94 kinds of edible plant extracts obtained from the Korea Plant Extract Bank were screened for cytotoxicity, following which the total phenolic content of 24 shortlisted extracts was determined. Of these, extracts from three plants, namely, (CC) leaf, (CJ) fruit, and (VD) leaf, were examined for antioxidant capabilities by measuring radical scavenging activity, ferric reducing/antioxidant power, and lipid peroxidation inhibitory activity.
View Article and Find Full Text PDFDue to metastatic potential and drug resistance, cancer stem cells (CSCs) have become a critical target for the development of chemotherapeutic agents. Recent studies showed that CSCs highly express NF-E2-related factor 2 (Nrf2)-mediated antioxidant enzymes and thereby retain relatively low levels of reactive oxygen species (ROS). Since anticancer agents usually utilize ROS as an arsenal for killing cancer cells, we hypothesized that inhibition of Nrf2 activity could increase the sensitivity of CSCs to anticancer drugs, and thus enhancing their therapeutic efficacy.
View Article and Find Full Text PDF